Company news
Knight Therapeutics, Inc. news in 2025
Knight Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris
December 18, 2025
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris
December 18, 2025
Knight Therapeutics Reports Third Quarter 2025 Results
November 6, 2025
Knight Announces Closing of US$100 Million Revolving Credit Facility
October 31, 2025
Knight Therapeutics Announces Launch of JORNAY PM(TM) in Canada
October 30, 2025
Knight Therapeutics Announces Launch of JORNAY PM™ in Canada
October 30, 2025
Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call
October 30, 2025
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
October 30, 2025
Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada
October 7, 2025
Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada
October 7, 2025
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada
October 7, 2025
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada
October 7, 2025
Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies
September 26, 2025
Knight Announces Normal Course Issuer Bid
August 20, 2025
Knight Therapeutics Reports Second Quarter 2025 Results
August 7, 2025
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico
August 5, 2025
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
August 4, 2025
Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call
August 1, 2025
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil
July 31, 2025
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
July 18, 2025
Knight Therapeutics Announces Closing of Previously Announced Acquisition of Paladin
June 17, 2025
Knight Closes US$50 Million Revolving Credit Facility with NBC
June 17, 2025
Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio
June 5, 2025
Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City
May 13, 2025
Knight Therapeutics Reports First Quarter 2025 Results
May 8, 2025
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
May 7, 2025
Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico
May 7, 2025
Notice of Knight Therapeutics' First Quarter 2025 Results Conference Call
May 1, 2025
Knight to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
April 29, 2025
Knight Therapeutics Inc. ranks on The Globe and Mail’s sixth-annual Women Lead Here benchmark of executive gender diversity
March 28, 2025
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
March 26, 2025
Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results
March 20, 2025
Notice of Knight Therapeutics' Fourth Quarter and Year End 2024 Results Conference Call
March 13, 2025
Knight Therapeutics to Acquire Paladin
March 11, 2025
Calls in 2025
Decks in 2025
- Q2 2025 Earnings Presentation
Earnings · 21 slides · Aug 7, 2025